Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect
Open Access
- 8 February 2018
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
Abstract
NK cell–based immunotherapies have been gaining traction in the clinic for treatment of cancer. IL-15 is currently being used in number of clinical trials to improve NK cell expansion and function. The objective of this study is to evaluate the effect of repetitive IL-15 exposure on NK cells. An in vitro model in which human NK cells are continuously (on on on) or intermittently (on off on) treated with IL-15 was used to explore this question. After treatment, cells were evaluated for proliferation, survival, cell cycle gene expression, function, and metabolic processes. Our data indicate that continuous treatment of NK cells with IL-15 resulted in decreased viability and a cell cycle arrest gene expression pattern. This was associated with diminished signaling, decreased function both in vitro and in vivo, and reduced tumor control. NK cells continuously treated with IL-15 also displayed a reduced mitochondrial respiration profile when compared with NK cells treated intermittently with IL-15. This profile was characterized by a decrease in the spare respiratory capacity that was dependent on fatty acid oxidation (FAO). Limiting the strength of IL-15 signaling via utilization of an mTOR inhibitor rescued NK cell functionality in the group continuously treated with IL-15. The findings presented here show that human NK cells continuously treated with IL-15 undergo a process consistent with exhaustion that is accompanied by a reduction in FAO. These findings should inform IL-15–dosing strategies in NK cell cancer immunotherapeutic settings.Keywords
Funding Information
- NIH (CA65493)
- NIH (CA111412)
- NIH (CA197292)
- NIH (HL122216)
- NIH (HL56067)
- NIH (HL11879)
- DOD (CA150085)
This publication has 44 references indexed in Scilit:
- Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cellsBlood, 2012
- Densely Granulated Murine NK Cells Eradicate Large Solid TumorsCancer Research, 2012
- Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent functionBlood, 2012
- NK Cells—From Bench to ClinicTransplantation and Cellular Therapy, 2012
- Mitochondrial Respiratory Capacity Is a Critical Regulator of CD8+ T Cell Memory DevelopmentImmunity, 2012
- Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Rα complexesProceedings of the National Academy of Sciences of the United States of America, 2010
- Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of CancerJournal of Medicinal Chemistry, 2010
- Suppressor of Cytokine Signaling 2 Regulates IL-15–Primed Human NK Cell Function via Control of Phosphorylated Pyk2The Journal of Immunology, 2010
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1Published by Elsevier BV ,2009
- Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancerBlood, 2005